P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 886-900

  Kuttesch, J F ^a   Parham, D M ^a   Luo, X ^a   Meyer, W H ^a   Bowman, L ^a   Shapiro, D N ^a   Pappo, A S ^a   Crist, W M ^a   Beck, W T ^a   Houghton, P J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; GLYCOPROTEIN P; MONOCLONAL ANTIBODY;

ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RHABDOMYOSARCOMA; TREATMENT FAILURE;

EID: 9044229147     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.886     Document Type: Article

References (79)

1. Raney J, Hays DM, Tefft M, et al: Rhabdomyosarcoma and the undifferentiated sarcomas, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott, 1989, pp 635-658
2. Maurer HM, Beltangady M, Gehan EA, et al: The intergroup rhabdomyosarcoma study-I: A final report. Cancer 61:209-220, 1988
3. Maurer HM, Gehan EA, Beltangady M, et al: The intergroup rhabdomyosarcoma study-II. Cancer 71:1904-1922, 1993
4. Crist WM, Beltangady MS, Gehan E, et al: Prognosis in children with rhabdomyosarcoma: A report of the intergroup rhabdomyosarcoma studies I and II. J Clin Oncol 8:443-452, 1990
5. Shapiro DN, Parham DM, Douglass EC, et al: Relationship of tumor cell ploidy to histologic subtype and treatment outcome in children and adolescents with unrestable rhabdomyosarcoma. J Clin Oncol 9:159-166, 1991
6. Pappo AS, Crist WM, Kuttesch J, et al: Tumor cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. J Clin Oncol 11:1901-1905, 1993
7. Newton WA, Soule EH, Hamoudi AB, et al: Histopathology of childhood sarcomas, intergroup rhabdomyosarcoma studies I and II: Clinicopathologic correlation. J Clin Oncol 6:67-75, 1988
8. DeVita VT, Jr: The problem of resistance. Principles & practice of oncology. 11:1-12, 1990
9. Beck WT: Mechanisms of multidrug resistance in humans tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 17:11-20, 1990 (suppl A)
10. Ling V: P-glycoprotein-mediated multidrug resistance to cancer chemotherapy. Adv Oncol 9:3-9, 1993
11. Roninson IB: The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43:95-102, 1992
12. Juranka PF, Zastawny RL, Ling V: P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583-2592, 1989
13. Cordon-Cardo C, O'Brien JP, Boccia J, et al: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287, 1990
14. Goldstein LJ, Fojo AT, Ueda K, et al: Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 8:128-136, 1990
15. Sato H, Gottesman MM, Goldstein LJ, et al: Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 14:11-22, 1990
16. Marie J, Zittoun R, Sikic BI: Multidrug resistance (mdr-1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592, 1991
17. Campos L, Guyotat D, Archimbaud E, et al: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476, 1992
18. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94, 1991
19. Garberoglio C, Dudas M, Casper ES, et al: Expression of P-glycoprotein in normal muscle cells and myogenic tumors. Arch Pathol Lab Med 116:1055-1061, 1992
20. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989
21. Schlaifer D, Laurent G, Chittal S, et al: Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 62:177-182, 1990
22. Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160-7164, 1990
23. Hegewisch-Becker S, Fliegner M, Tsuruo T, et al: P-glycoprotein expression in normal and reactive bone marrows. Br J Cancer 67:430-435, 1993
24. Weinstein RS, Jakate SM, Dominguez JM, et al: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720-2726, 1991
25. Dalton WS, Grogan TM, Meltzer P, et al: Drug-resistance in multiple myeloma and non-hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424, 1989
26. List AF, Spier C, Greer J, et al: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652-1660, 1993
27. Chan HSL, Haddad G, Thorner PS, et al: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614, 1991
28. Chan HSL, Thorner P, Haddad G, et al: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704, 1990
29. Nakagawara A, Kadomatsu K, Sato S, et al: Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 50:3043-3047, 1990
30. Leuschner I, Schmidt D, Hoffmann H, et al: Expression of p-glycoprotein in soft tissue tumors of childhood correlation to treatment response. J Cancer Res Clin Oncol 117:510-514 117:S97, 1993 (suppl 3, abstr)
31. Leuschner I, Schmidt D, Hoffmann H, et al: Expression of p-glycoprotein in soft tissue tumors of childhood correlation to treatment response. J Cancer Res Clin Oncol 117:510-514 117:S97, 1993 (suppl 3, abstr)
32. Dalton WS, Grogan TM, Rybski JA, et al: Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 73:747-752, 1989
33. Horton JK, Houghton JA, Houghton PJ: Expression of multidrug resistance gene (mdr1) in human tumor xenografts sensitive and resistant to natural products: Failure to predict chemosensitivity. J Cell Pharmacol 2:208-216, 1991
34. Shen D, Cardarelli C, Hwang J, et al: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261:7762-7770, 1986
35. Beck WT, Muller TJ, Tanzer LR: Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39:2070-2076, 1979
36. Ueda K, Cardarelli C, Gottesman MM, et al: Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004-3008, 1987
37. Chan HSL, Haddad G, Thorner PS, et al: P-glycoprotein expression as a predictor of the outcome of therapy for Ewing's sarcoma. Proc Annu Meet Am Assoc Cancer Res 34:A1370, 1993 (abstr)
38. Favrot M, Combaret V, Goillot E, et al: Expression of p-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 64:233-238, 1991
39. Hijazi YM, Axiotis CA, Navarro S, et al: Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primative neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 102:61-67, 1994
40. Qian X, Beck WT: Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res 50:1132-1137, 1990
41. Georges E, Bradley G, Gariepy J, et al: Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87:152-156, 1990
42. Kartner N, Evernden-Poreile D, Bradley G, et al: Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820-823, 1985
43. Scheper RJ, Bulte JWM, Brakkee JGP, et al: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 42:389-394, 1988
44. Cordell JL, Falini B, Erber WN, et al: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-229, 1984
45. Beckstead JH: Improved antigen retrieval in formalin-fixed, paraffin-embedded tissues. Applied Immunohistochem 2:274-281, 1994
46. Chomezynski P, Sacchi N: Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
47. Kingston RE, Chomezynski P, Sacchi D: Unit 4.2 Quanidium methods for total RNA preparation, in Ausubel FM, Brent R, Kingston RE, et al (eds): Current Protocols in Molecular Biology. New York, NY, Wiley, 1994
48. Brown T: Unit 4.9 Analysis of RNA by northern hybridization, in Ausubel FM, Brent R, Kingston RE, et al (eds): Current Protocols in Molecular Biology. New York, NY, Wiley, 1994
49. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
50. Harlow E, Lane D: Antibodies - A Laboratory Manual. New York, NY, Cold Spring Harbor Laboratory, 1988
51. 2-microglobulin to distinguish peripheral neuroepithelioma from neuroblastoma. Hum Pathol 24:880-885, 1993
52. Conover WJ: Practical Nonparametric Statistics (ed 2). New York, NY, Wiley, 1980
53. Agresti A: Categorical Data Analysis. New York, NY, Wiley, 1990
54. Fleiss JL: Statistical Method for Rates and Proportions (ed 2). New York, NY, Wiley, 1981
55. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
56. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
57. Lehmann E: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden-Day, 1975
58. Pratt CB, Hustu HO, Kumar PM, et al: Treatment of childhood rhabdomyosarcoma at St Jude Children's Research Hospital, 1962-78. Natl Cancer Inst Monogr 56:93-101, 1981
59. Etcubanas E, Horowitz M, Vogel R: Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 69:999-1000, 1985
60. Horowitz ME, Etcubanas E, Christensen ML, et al: Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development. J Clin Oncol 6:308-314, 1988
61. Pappo A, Etcubanas E, Santana VM, et al: A phase II trial of ifosfamide in previously untreated children and adolescents unresectable rhabdomyosarcoma. Cancer 71:2119-2125, 1993
62. Chan HSL, DeBoer G, Thorner PS, et al: Multidrug resistance: Clinical opportunities in diagnosis and circumvention. Hematol Oncol Clin North Am 8:383-410, 1994
63. Thiebaut F, Tsuruo T, Hamada H, et al: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738, 1987
64. Grogan T, Dalton W, Rybski J, et al: Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63:815-824, 1990
65. Reisner HM, Wick MR: 1. Theoretical and technical considerations for the use of monoclonal antibodies in diagnostic immunohistochemistry, in Wick MR, Siegal GP (eds): Monoclonal Antibodies in Diagnostic Immunohistochemistry. New York, NY, Dekker, 1988, pp 1-49
66. Rao VV, Anthony DC, Piwnica-Worms D: MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 54:1536-1541, 1994
67. Sikic BI: Modulation of multidrug resistance: At the threshold. J Clin Oncol 11:1629-1635, 1993 (editorial)
68. Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454-462, 1988
69. Beck WT, Danks MK: Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 2:235-244, 1991
70. Black SM, Wolf CR: The role of glutathione-dependent enzymes in drug resistance. Pharmacol Ther 51:139-154, 1991
71. Kramer RA, Zakher J, Kim G: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241:694-697, 1988
72. Cole SPC, Bhardwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654, 1992
73. Lowe SW, Ruley HE, Jacks T, et al: p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
74. Salmon SE, Dalton WS, Grogan TM, et al: Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50, 1991
75. Miller TP, Grogan TM, Dalton WS, et al: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24, 1991
76. Yahanda AM, Adler KM, Fisher GA, et al: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624-1634, 1992
77. Cowie F, Pinkerton CR: Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance. J Clin Oncol 12:1998-1999, 1994
78. Fisher GA, Hausdorff J, Lum BL, et al: Phase I trial of etoposide with cyclosporin SDZ 833, a modulator of multidrug resistance. Proc Am Soc Clin Oncol 13:143, 1994 (abstr 368)
79. Giaccone G, Linn SC, Catimel G, et al: Phase I and pharmacokinetic study of PSC 833 po in combination with doxorubicin in patients with solid tumors. Proc Am Soc Clin Oncol 13:142, 1994 (abstr 364)